Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
about
TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative diseaseTransthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?Pro-inflammatory interleukin-18 increases Alzheimer's disease-associated amyloid-β production in human neuron-like cellsMyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's diseaseCD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimerAlzheimer's disease; taking the edge off with cannabinoids?Glial Tau Pathology in Tauopathies: Functional ConsequencesClinical perspectives of TRAIL: insights into central nervous system disordersGenetics ignite focus on microglial inflammation in Alzheimer's diseasePotential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's DiseaseRodent models of neuroinflammation for Alzheimer's diseaseACE overexpression in myelomonocytic cells: effect on a mouse model of Alzheimer's diseaseGlial cells in (patho)physiologyInflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?Alzheimer's-related peptide amyloid-β plays a conserved role in angiogenesisTherapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cellsDistinct Contributions of Astrocytes and Pericytes to Neuroinflammation Identified in a 3D Human Blood-Brain Barrier on a ChipOcular indicators of Alzheimer's: exploring disease in the retinaAlzheimer's disease and type 2 diabetes via chronic inflammatory mechanismsPotential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomicsThe Potassium Channel KCa3.1 Represents a Valid Pharmacological Target for Astrogliosis-Induced Neuronal Impairment in a Mouse Model of Alzheimer’s DiseaseEarly neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB miceThe Toll-->NFkappaB signaling pathway mediates the neuropathological effects of the human Alzheimer's Abeta42 polypeptide in DrosophilaSuppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in miceLoading into nanoparticles improves quercetin's efficacy in preventing neuroinflammation induced by oxysterolsTriptolide preserves cognitive function and reduces neuropathology in a mouse model of Alzheimer's diseaseEffects of Ranolazine on Astrocytes and Neurons in Primary CulturePioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-β and cerebrovascular pathologyA computational procedure for functional characterization of potential marker genes from molecular data: Alzheimer's as a case studyCumulative inflammatory load is associated with short leukocyte telomere length in the Health, Aging and Body Composition StudyGenetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's diseaseLRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β.Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearanceCognitive Deficits, Changes in Synaptic Function, and Brain Pathology in a Mouse Model of Normal Aging(1,2,3).Amyloid-beta and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive declineRole of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptideThe relation of genetic and environmental factors to systemic inflammatory biomarker concentrationsSystemic immune challenges trigger and drive Alzheimer-like neuropathology in mice.
P2860
Q21093232-7C82A17B-27FF-4BB8-BCCE-79B7ACA42AFBQ21202832-01D58D8C-2176-430D-BF61-E5E845C332CFQ21245229-6E0C47A2-A3EE-40AF-AB83-FFF3F980D739Q24616286-E1367081-5687-4F7D-9BC9-59F65B78F5E1Q24642646-7890363F-A332-4BAF-8B53-0C548F0793FAQ24681412-25423847-17F5-4769-A095-7F9C7A8C9C43Q26765365-A3D34814-DAF3-41F0-B2ED-F7EF84285CDFQ26766570-99173172-B1EB-472B-A7D8-A6E5C1A384C7Q26781865-395501B1-B50E-451F-92C1-8D243B3146F0Q26783325-3CE6EAC9-E2ED-4DD1-83EC-743A69A0428BQ26864804-236165BE-E081-4F01-AB45-EAF8F12B0058Q26866225-7597F50D-EEDD-418B-853F-F6B43987BF95Q27021135-1CA06FF2-DEEB-41B7-A448-D0B60950B266Q27022728-3E451180-FB46-4D2F-9D69-E692A3055EA1Q27300765-BD146EF3-1BBE-4A12-931D-968A7AC4D89BQ27303708-772B99B1-CE75-4835-A4B6-CE09D598ED88Q27303769-E246C383-53CC-48FA-BE92-283417BEF274Q27317159-7CF01498-FB31-4DFC-BF7E-BD38DEB41F9BQ27319805-04124ACA-AE5F-4083-9E3B-C9068D7357F7Q28078670-79AB9722-3E86-4185-AD51-9D11BFE3CADDQ28086892-FDD8BB43-3655-42F5-ADC5-446007E4D637Q28256439-E11C8169-D85E-4AAC-8E65-349DE6C78E7AQ28468424-105A3C84-DB0A-44F7-B658-FF232465CC79Q28472880-5EF3225F-B21E-4D82-A2D6-7723538FB780Q28474328-3C9043DB-A7D8-413E-BE1F-BBB0385B686DQ28533976-9803A389-7A99-4B4E-81C4-8E6BA2B5D83CQ28538558-70D5A0E1-4BA4-43ED-98D6-0FA21222AC7AQ28543501-1911D3DC-F387-4DCF-8BEA-3263A7FDFBC4Q28550579-4E2F96BC-1A0A-49CA-9237-265B694A8291Q28594423-AC7482E5-5F21-4180-8A40-97E5634B8685Q28741856-ACDA9494-EACE-4AF8-8B2B-2D5115F78788Q28744595-D09D981D-3B85-4F1C-AF44-1EA4DC694E38Q28748461-4BE8ADAF-5356-4004-883F-AB48E668D2E2Q29976920-35F5294A-3FA7-4A36-B918-7BB56282CA47Q30274556-B3B80AF0-AE47-4946-874C-8A43FA7EB7C1Q30401094-C424FFC5-2040-484C-AC0A-51965B9BB3C3Q30476347-B95DD5FC-6B13-4EA0-9E66-9D8AEA7EF332Q30490518-AB0D6F28-6B9C-43D8-8138-AB734724DD0FQ30495275-4BAA3FC1-9246-4C26-BACF-D8C4F6DFDB37Q30527791-E891C1B6-C36C-41CF-AB99-2016E27A6141
P2860
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@ast
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@en
type
label
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@ast
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@en
prefLabel
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@ast
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@en
P2860
P356
P1433
P1476
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
@en
P2093
Tony Wyss-Coray
P2860
P304
P356
10.1038/NM1484
P407
P577
2006-09-01T00:00:00Z